Tarsus Pharmaceuticals Inc expected to post a loss of $1.36 a share - Earnings Preview

Tarsus Pharmaceuticals

23/02/2024 13:57

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a fall in quarterly revenue when it reports  results on
February 27 for the period ending December 31 2023
    * The Irvine California-based  company is expected to report
a
43.3% decrease in revenue to $5.665 million from $10 million a
year ago, according to the mean estimate from 8 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Tarsus Pharmaceuticals
Inc is
for a loss of $1.36 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $50.00​, above​ its last closing price
of $31.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.29       -1.37      -1.28     Beat    6.3
 Jun. 30 2023  -1.06       -1.08      -1.17     Missed  -8.5
 Mar. 31 2023  -0.92       -0.94      -0.88     Beat    6.9​
 Dec. 31 2022              -0.69      -0.49     Beat    29
 ​​Sep.        -0.88       -0.97      -0.84     Beat    13.7
 30 2022                                                
 Jun. 30 2022  -0.61       -0.59      -0.24     Beat    59.4​
 Mar. 31 2022  -1.06       -0.92      -0.98     Missed  -6.8
 Dec. 31 2021  -0.76       -0.73      -0.72     Beat    1
 This summary was machine generated February 23 at 13:57 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)